Brief: Quest Pharmatech Signs License Agreement With Oncocare Therapeutics
28/11/2018 14:32
Nov 28 (Reuters) - Quest Pharmatech Inc QPT.V :
* QUEST PHARMATECH SIGNS LICENSE AGREEMENT WITH ONCOCARE
THERAPEUTICS TO DEVELOP AND COMMERCIALIZE TARGETED CANCER
THERAPY TECHNOLOGY IN THE U.S.
* QUEST PHARMATECH INC - IN RETURN FOR GRANTING LICENSE
RIGHTS TO
U.S., CO WILL RECEIVE A 45% OWNERSHIP INTEREST IN ONCOCARE
THERAPEUTICS
Source text for Eikon: ID:nCNW4Cjlza
Further company coverage: QPT.V
(Reuters.Briefs@thomsonreuters.com)
Recent news on Quest PharmaTech
See all newsBrief: Quest Pharmatech Announces Change Of Chief Executive Officer
Brief: Quest Pharmatech Provides Product Development Update
Brief: Quest PharmaTech Clarifies Agreement in Principle with OQP Bio
Brief: Quest Pharmatech Provides Corporate Update
Brief: Quest PharmaTech Announces Sale Of Bioceltran Investment And Return Of Photodynamic Therapy Technology License